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Abstract
The dysregulation of vascular endothelial cells by thrombin has been implicated in the development of a number of
pathologic disorders such as inflammatory conditions, cancer, diabetes, coronary heart disease. However, transcriptional
regulation of vascular endothelial cells by thrombin is not completely understood. In the present study, Illumina RNA-seq
was used to profile the transcriptome in human pulmonary microvascular endothelial cells (HMVEC-L) treated with
thrombin for 6 h to gain insight into thrombin’s direct effects on the endothelial function. Out of 100 million total reads
from a paired end sequencing assay, 91–94% of the reads were aligned to over 16,000 genes in the reference human
genome. Thrombin upregulated 150 known genes and 480 known isoforms, and downregulated 2,190 known genes and
3,574 known isoforms by at least 2 fold. Of note, thrombin upregulated 1,775 previously unknown isoforms and
downregulated 12,202 previously unknown isoforms by at least 2 fold. Many genes displayed isoform specific differential
expression levels and different usage of transcriptional start sites after the thrombin treatment. The cross comparisons
between our RNA-seq data and those of DNA microarray analysis of either 6 h thrombin treated HUVEC or 5 h TNFa treated
HMVEC have provided a significant overlapping list of differentially expressed genes, supporting the robust utility of our
dataset. Further in-depth follow-up analysis of the transcriptional regulation reported in this study may shed light on
molecular pathogenic mechanisms underlying thrombin mediated endothelial dysfunction in various diseases and provide
new leads of potential therapeutic targets.
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Introduction
Endothelial cells lining the inner surface of microvessels form a
semipermeable barrier that actively participates in blood–tissue
exchange of plasma fluid, proteins and cells. The precise re-
gulation of endothelial barrier and function is essential for
maintaining circulatory homeostasis and the physiological function
of different organs. The dysregulation of microvascular barrier and
function represent crucial events in the development of a variety of
disease processes, such as adult respiratory distress syndrome,
ischemia–reperfusion injury, diabetic vascular complications, and
tumor metastasis [1].
It is now understood that while increased circulating levels of
soluble mediators such as thrombin, pro-inflammatory cytokines
such as TNFa, and immune cells such as neutrophils are a
hallmark of host defense against injury, most of these mediators
target the vascular endothelium to produce vasoactive and
cytotoxic effects [1]. Thrombin is a serine protease. Besides its
central role in the coagulation cascade acting as both a coagulant
factor and an anticoagulant factor, thrombin can trigger important
cellular effects via a protease-activated receptor pathway or
receptor independent pathways [2]. Thrombin can stimulate
endothelial cells and regulate the expression, release and activation
of a number of biological mediators. Thrombin is known for its
endothelial hyperpermeability effect. Thrombin can protect
endothelial cells from apoptosis [3].. Thrombin plays an important
role in angiogenesis and is thus involved in tumor progression and
metastasis [4]. The list of physiological and pathological roles of
thrombin is still expanding. The understanding of these events at a
molecular level will provide new targets of therapeutic interven-
tions in disease states.
With the advent of next generation DNA sequencing technol-
ogies [5], such as RNA-seq, a more comprehensive and accurate
transcriptome analysis has become feasible and affordable. RNA-
seq first sequences complementary DNA (cDNA) in short
fragments and subsequent mapping of such short sequence
fragments (reads) onto the reference genome. RNA-Seq enables
identification of transcription initiation sites (TSSs) and new
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e31229splicing variants, and it permits a precise quantitative determina-
tion of exon and splicing isoform expression [6]. In the present
study, we performed a comprehensive transcriptome analysis in
human pulmonary microvascular endothelial cells (HMVEC-L)
treated with or without thrombin using the Illumina RNA-Seq
technique. We found significant differences in gene isoform
expression levels, alternated use of promoters and transcription
start sites between control and thrombin treated HMVEC-L.
These data provided broader and deeper insights into thrombin’s
transcriptional regulation on the vascular endothelial functions
and it also provides rich reagents for further experimentations.
Results
Quality analysis of RNA-Seq data
Real-time analysis of the sequencing run, including several
measurements, was performed by the Illumina HiSeq Control
Software. Clusters of identical sequences were generated on the
Illumina cBot and the number of those clusters was reported,
along with the percentage of those clusters passing an internal
quality filter. Across the 5 samples, between 599,000 and 621,000
raw clusters were detected, with a median of 603,000 clusters per
lane. Between 89.5% and 92.1% of those clusters passed the filter,
with a median of 91.3% of the clusters passing the filter. Each lane
was aligned in real-time with the PhiX genome and between 0.6%
and 0.7% of the clusters aligned. Our control lane of PhiX
produced 357,000 clusters with 96.9% passing the filter and 99.1%
aligning to the PhiX genome. All these values were within the
recommended limits established by Illumina.
Post-run quality analysis of RNA-Seq Data was carried out as
described by Twine et al. [7]. The total number of reads produced
from each sample was between 97,478,180 and 105,351,222, with
a median across all samples of 102,568,132 (Table 1). The
difference in the number of reads between the control samples and
the thrombin samples was not statistically significant (Student’s t-
test, p=0.88). To assess the quality of the reads, data was pulled
from the TopHat log files as well as the output files. Between
0.31% and 0.34% of the reads were removed due to low quality
before mapping to the reference genome began. Between 88.4%
and 94.2% of the total reads mapped to the human genome. To
ensure the uniform coverage across the genome, the data was
visualized using a local copy of the Integrative Genomics Viewer.
We mapped the control A reads against chromosome 1 (Figure 1).
The average alignment was computed across the genome and
those alignment scores were log-transformed (base 2) to better
visualize the full range of the data. As expected, no reads mapped
to the centromere or areas of the chromosome without genes.
Differentially expressed genes
After mapping the sequencing reads to the reference genome
with TopHat, transcripts were assembled and their relative
expression levels were calculated with Cufflinks in FPKM. Then,
the sub-program, Cuffdiff was used to calculate the differential
expression on both a gene level and a transcript level, as well as the
calculation of alternative promoter usage and alternative splicing.
Cufflinks calculates the differential gene expression with the ratio
of the thrombin treated group to the control group for every gene
and transcript along with the statistical significance of the values.
Overall, there are 16,636 expressed genes in the control cells
and 16,357 expressed genes in thrombin treated genes, which were
aligned to the reference genome (Table 2). There are 783 genes,
whose expressions were only detected in the control cells, while
504 genes whose expressions were only detected in thrombin
treated cells. The differentially expressed genes in thrombin
treated cells over the controls with statistically significant fold
changes ranged from 216.32 to 94.23. There are 152 upregu-
Figure 1. A transcription profile of HMVEC cells (Control A) for chromosome 1. The RNASeq read density plotted along chromosome 1 is
shown. Average alignment was computed by igvtools. The coverage values were measured along intervals of the genome. These intervals vary in size
depending on how variable the read density is for a particular genomic location. Each bar represents the log2 frequency of reads plotted against
chromosome coordinates.
doi:10.1371/journal.pone.0031229.g001
Table 1. RNA-Seq sequence reads mapping to UCSC Human genome build 19 by TopHat v1.3.0/Bowtie v0.12.7.
Control Thrombin
A B Average A A2 B Average
Total reads 102,399,460 102,568,132 102,483,796 105,351,222 103,170,324 97,478,180 101,999,909
Reads removed 0.32% 0.31% 0.31% 0.33% 0.32% 0.34% 0.33%
Read aligned to reference genome 94.2% 93.4% 93.5% 93.5% 92.4% 88.4% 91.5%
Total reads and the percentage of those reads removed due to low quality and aligned to hg19 by TopHat. TopHat allows two mismatches when aligning to a reference
genome.
doi:10.1371/journal.pone.0031229.t001
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with at least 2 fold change over the control cells (Table 2). As for
known isoforms, there are 26,807 in the control cells and 26,300 in
thrombin treated genes. Among them, there are 1,492 known
isoforms, whose expressions were detected only in the control cells,
while 985 known isoforms whose expressions were detected only in
thrombin treated cells. The differentially expressed known
isoforms in thrombin treated cells over the controls with
statistically significant fold changes ranged from 2126.25 to
962.57. There are 480 upregulated- and 3,574 downregulated-
known isoforms in thrombin treated cells by at least 2 fold change
over the control cells (Table 2). For novel isoforms whose
annotations are not known in the current reference gene or
transcript database, there are 25,880 in the control cells and
25,886 in thrombin treated genes. Among them, there are 418
novel isoforms, whose expressions were only detected in the
control cells, while 424 novel isoforms whose expressions were
only detected in thrombin treated cells. The differentially
expressed novel isoforms in thrombin treated cells over the
controls with statistically significant fold changes ranged from
2927.74 to 431.33. There are 1,775 upregulated- and 12,202
downregulated- novel isoforms in thrombin treated cells by at least
2 fold change over the control cells (Table 2).
Top 10 up- and down- regulated genes in thrombin treated
HMVEC cells are presented in Figure 2. The expanded list of top
50 up- and down- regulated genes in thrombin treated HMVEC
cells are presented in the supplement (Table S1). Protocadherin a1
(PCDHA1) and a11 (PCDHA11) stand out as the top two most
upregulated genes in thrombin treated HMVEC cells, respectively.
PCDHA1 was upregulated by 94 fold, while PCDHA11 was
upregulated by 59 fold. Among the top upregulated genes, TNF
receptor-associated factor 1 (TRAF1) and chemokine C-X3-C
motif ligand 1 (C-X3-CL1), both of which are associated with
the inflammatory response, were upregulated by 8 and 6 fold,
respectively. Arsenic (+3 oxidation state) methyltransferase
(AS3MT), which is involved in oxidative stress, was upregulated
by 7 fold. Ghrelin opposite strand RNA (GHRLOS) and im-
munoglobulin superfamily member 10 (IGSF 10) are the top two
most downregulated genes in thrombin treated HMVEC cells.
They were downregulated by 75 and 50 fold, respectively. The
majority of genes presented in Figure 2 have not yet been
identified in the literature to be differentially regulated by
thrombin. One fourth of those top regulated genes in Figure 2
(LOC441617, LOC728066, LOC100132215 and C2orf66d) are
currently not annotated. In the top 50 up- and down- regulated
genes in thrombin treated HMVEC cells in Table S1, about 10%
of them are not annotated.
Top 10 up- and down- regulated known isoforms in thrombin
treated HMVEC cells are presented in Figure 3. The expanded list
of top 50 up- and down- regulated known isoforms in thrombin
treated HMVEC cells are presented in the supplement (Table S2).
The fold change among top 50 up- regulated known isoforms in
thrombin treated HMVEC cells varies from 12 to 963. The fold
change among top 50 down- regulated known isoforms in
thrombin treated HMVEC cells varies from 224 to 21455.
Consistent with the finding that PCDHA1 and PCDHA11 are the
top regulated genes (Table 1), both genes are among the top
regulated known isoforms in thrombin treated HMVEC cells
(Figure 3 and Table S2). Another two known isoforms of the
protocadeherin gene family [protocadherin gamma gene B6
(PCDHGB6) and PCDHA3] were also upregulated by 82 and
22 fold, respectively. One of the hemochromatosis (HFE) gene
isoforms was the highest upregulated isoform (983 fold) by
thrombin. HFE is known to be involved in iron metabolism. It
may also be involved in a tissue injury and reparative process [8].
Phospholipase C- beta 4 (PLCB4) was the highest down regulated
isoform (21455 fold) by thrombin. Phospholipase C-beta
hydrolyses phosphatidylinositol 4,5-bisphosphate and generates
inositol 1,4,5-trisphosphate in response to activation of various G
protein-coupled receptors. PLCB4 was implicated in the delayed
[Ca2+]i increase in response to the stimulation by thrombin [9].
Among the top ten up- and down-regulated known gene isoforms
by thrombin are three presumable transcription factors (runt-
related transcription factor 1, forkhead box P2, zinc finger and
BTB domain containing 20) and two ion channel gene isoforms
(sodium channel and voltage-gated type IV beta, and sodium/
calcium exchanger member 3). Two different isoforms of the gene
ZBTB20 are listed among the top ten down-regulated known gene
isoforms by thrombin. They differ in the region of their
untranslated first exons.
The top 10 up- and down- regulated novel isoforms in thrombin
treated HMVEC cells are presented in Table 3. The expanded list
of top 50 up- and down- regulated novel isoforms in thrombin
treated HMVEC cells are presented in the supplement (Table S3).
The fold change among top 50 upregulated novel isoforms in
thrombin treated HMVEC cells varies from 15 to 431. The fold
change among top 50 downregulated novel isoforms in thrombin
treated HMVEC cells varies from 244 to 2928. Integrin alpha
FG-GA repeat containing 2 (ITFG2), a novel isoform of integrin
alpha, was the highest upregulated novel isoform (431 fold) by
thrombin. Integrins are heterodimeric membrane receptors
consisting of a and b subunits, that play a pivotal role to
Table 2. Gene/Isoform expression summary.
Genes
Control Thrombin
Total Genes Expressed 16,636 16,357
Control Only 783
Thrombin Only 504
Up-regulated (2-fold or greater difference) 152
Down-regulated (2-fold or greater difference) 2,190
Known Isoforms
Control Thrombin
Total Known Isoforms Expressed 26,807 26,300
Control Only 1,492
Thrombin Only 985
Up-regulated (2-fold or greater difference) 480
Down-regulated (2-fold or greater difference) 3,574
Novel Isoforms
Control Thrombin
Total Novel Isoforms Expressed 25,880 25,886
Control Only 418
Thrombin Only 424
Up-regulated (2-fold or greater difference) 1,775
Down-regulated (2-fold or greater difference) 12,202
Genes, known isoforms and novel isoforms expressed in control and thrombin-
treated HMVEC cells. Expression determined by CuffDiff, after Benjamini-
Hochberg correction. The fold change is the ratio of thrombin FPKM to control
FPKM.
doi:10.1371/journal.pone.0031229.t002
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ton across the plasma membrane [10]. Three isoforms of Zinc
finger protein 518A were among the top one, three and five
highest down regulated novel isoforms by thrombin (2928, 738,
and 262 fold) respectively. Two upregulated novel isoforms come
from two cytoskeleton proteins: non-erythrocytic 2 spectrin beta
(SPTBN2) and fibrillin 2 (FBN2). More than one fourth of top 10
up- and down- regulated novel isoforms in thrombin treated
HMVEC cells (6/20) are from unannotated genes (Table 3). Three
different novel isoforms of the gene ZNF518A are listed among top
ten downregulated unknown gene isoforms by thrombin. All these
three novel isoforms are longer than any known isoforms of the
gene ZNF518A.
Network and pathway analysis of differentially expressed
genes
The differentially expressed gene lists of a 2-fold or greater
change after the thrombin treatment were submitted to Ingenuity
Pathway Analysis (IPA) v9.0-3211 (Ingenuity Systems, Inc.,
Redwood City, CA). Networks of Network Eligible Molecules, as
described in the Method section, were then algorithmically
generated based on their connectivity. Networks affected by
upregulated genes/isoforms after thrombin treatment of HMVEC
cells are listed in Table 6. Networks affected by downregulated
genes/isoforms after thrombin treatment of HMVEC cells are listed
in Table 7. Notably, inflammatory response is among the top
networks of both upregulated genes and isoforms by thrombin
(Table 4). Some of genes involved in anti-inflammatory response
were downregulated by thrombin (Table 5). This could provide a
molecular insight into the known notion that thrombin plays a
significant role in inflammatory diseases [11]. Other top affected
networks are Cell-To-Cell Signaling and Interaction, Tissue
Morphology, Cellular Movement (Table 4 and 5). These observa-
tions are consistent with known functions of thrombin that can
cause dissociation of cell-cell junctions between endothelial cells as
well as cytoskeleton contraction, leading to a widened intercellular
space that facilitates transendothelial flux [1].
Canonical pathways analysis identified the pathways from the
Ingenuity Pathways Analysis library of canonical pathways that
were most significant to the data set. Genes with a 2-fold or greater
change in expression after thrombin treatment and that were
associated with a canonical pathway in Ingenuity’s Knowledge
Base were considered for the analysis. Top canonical pathways
affected by upregulated genes/isoforms after thrombin treatment
of HMVEC cells are listed in Table 6. Top canonical pathways
affected by downregulated genes/isoforms after thrombin treat-
ment of HMVEC cells are listed in Table 7. In concordance with
the above observation that top affected networks by thrombin is
inflammatory response, nearly all top canonical pathways affected
by upregulated genes/isoforms after thrombin treatment are
related to inflammatory response. IL17A is a proinflammatory
cytokine produced by activated T cells. This cytokine regulates the
activities of NF-kappaB and mitogen-activated protein kinases.
This cytokine can stimulate the expression of IL6 and cyclooxy-
genase-2 (PTGS2/COX-2), as well as enhance the production of
nitric oxide (NO). High levels of this cytokine are associated with
several chronic inflammatory diseases including rheumatoid
arthritis, psoriasis and multiple sclerosis [12]. TREM-1 is a
Figure 2. Top 10 up-/down-regulated genes in thrombin treated HMVEC. The differentially expressed genes in thrombin treated HMVEC vs
those in control cells were determined by CuffDiff, after Benjamini-Hochberg correction. The fold change is the ratio of FPKM of those genes in
thrombin treated HMVEC to FPKM of those genes in control cells. The differentially expressed genes were ranked on their fold change and the 10
with the highest or lowest fold changes are shown here. The full name of each gene symbol is provided in text and Table S1.
doi:10.1371/journal.pone.0031229.g002
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CD40L are considered as neo-inflammatory molecules in vascular
diseases [14]. In addition, Enhanced triggering receptor expressed
on myeloid cells 1 (TREM1) Signaling may provide a new signal
transduction pathway on the effect of Thrombin stimulated
calcium influx into the cells since a novel TREM1 member,
TREM-like transcript-1, can enhance calcium signaling via SHP-2
[15]. DNA Double-Strand Break Repair and BRCA1 in DNA
Damage Response are top canonical pathways affected by down-
regulated genes/isoforms after thrombin treatment of HMVEC
cells (Table 7). Dysfunction of DNA repair pathways is among the
major causes of tumorogenesis [16]. Mutated BRCA1 or 2,
essential components of a repair pathway for repairing DNA
double-strand breaks, underlie the pathogenesis of breast or
ovarian cancers [16]. Thrombin is recognized as a potent mitogen
in cancer and tumor metastasis [17]. The observation provided in
Table 7 may shed a new light into the molecular mechanisms
underlying thrombin in the tumor pathogenesis.
We also examined differentially expressed genes in traditional
thrombin signaling pathway (Figure 4 and Table S4). Notably,
6 h thrombin treatment significantly upregulated thrombin
receptor Par4 and down-regulated thrombin receptor Par 3
while there was no change in the expression of thrombin receptor
Par 1. Expression of NFkB1, NF kB2 and Src was also
significantly upregulated. Some of Rho family genes (Rho B, C,
F and G) were upregulated while others (Rho J, Q, T1, U and V)
were down regulated (Table S4). Myosin light chain gene 9
(MYL9) was upregulated while MYL12B was downregulated.
Expression of other genes was either down-regulated or not
affected.
Detailed analysis of the differentially regulated
protocadherin gene by Thrombin
Protocadherin gene is of particular interest due to its multiple
isoforms, which varied from upregulation to downregulation after
thrombin treatment of HMVEC cells. The mapping of reads for all
protocadherin alpha isoforms except PCDHA2 and PCDHA5 ,
which are expressed in control cells but not thrombin-treated cells,
to the reference genome shows differences in averaged expression
levels for protocadherin alpha isoform exons between normal
controls and thrombin-treated group (Fig. 5A). A histogram shows
the fold changes between thrombin-treated HMVEC cells and
control cells, as calculated by CuffDiff (Fig. 5B). Different
protocadherin alpha isoforms from PCDHA1 to PCDHA13 except
PCDHA2 and PCDHA5 responded to the thrombin treatment
differently from the downregulation by 26.46 folds (PCDHA12) to
the upregulation by 94.23 fold (PCDHA1). This result suggests that
onePCDHisoform could function differently from another isoform.
Gene isoforms are often produced by alternative splicing. The
alternative spliced forms of PCDHA1, 11, 3, 10, 12, 6 were among
the top ten up- and down- regulated genes showing alternative
splicing in thrombin treated HMVEC cells (Table S5). Four
protocadherin alphafamilymembers, protocadherinalpha10,3,11
and 1, were among the top 50 up- and down- regulated genes with
alternative promoter usage in thrombin treated HMVEC cells
(Table S6). Focusing on Protocadherin gene expression in the
Figure 3. Top 10 up-/down-regulated gene isoforms in thrombin treated HMVEC. The differentially expressed gene isoforms in thrombin
treated HMVEC vs those in control cells were determined by CuffDiff, after Benjamini-Hochberg correction. The fold change is the ratio of FPKM of
those gene isoforms in thrombin treated HMVEC to FPKM of those in control cells. The differentially expressed gene isoforms were ranked on their
fold change and the 10 with the highest or lowest fold changes are shown here. The full name of each gene isoform symbol is provided in text and
Table S2.
doi:10.1371/journal.pone.0031229.g003
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RNA-Seq and Cufflinks can identify not only transcriptional
regulation of a gene but also post-transcriptional regulation of
primary transcripts via alternative splicing.
Validation of three differentially regulated genes by qRT-PCR
To validate the RNA-seq results in this study using an alternative
approach, we performed a qRT-PCR experiment to assay three
different genes (Figure 6). In RNA-seq data, TNF receptor-associated
factor 1 (TRAF1) was upregulated by 7.96 fold; CUGBP, Elav-like
family member 1 (CELF1) was down-regulated by 1.16 fold; and
Fanconi anemia, complementation group D2 (FANCD2) was down-
regulated by 1.70 fold. In qRT-PCR data, these corresponding
numbers are +7.25fold,21.15 fold and 22.07fold,respectively.The
resultsofthesethreegenesassayedbyRNA-seqandqRT-PCRarein
good agreement, which corroborates our RNA-seq results.
Discussion
Our study provides the first comprehensive insight into the
transcriptome of human pulmonary microvascular endothelial
cells treated with thrombin using RNA-seq, a powerful next-
generation DNA sequencing platform, since a literature search for
the PubMed database with the combination of key words of
thrombin and RNA-seq retrieves zero records as of Sept. 16, 2011.
For RNA-seq, we used the Illumina HiScanSQ instrument to
perform a 26101 paired end run for all of our samples. The
advantage of a paired end run is that both reads contain long
range positional information, allowing for highly precise alignment
of reads. We calculated the number of differentially expressed
genes between thrombin treated cells and controls based on mean
values of two duplicated samples in each group. We obtained a
mean value of 102,568,132 reads per sample, which is more than
enough to deliver sufficient sequence coverage for transcriptome
profiling according to a previous report by Sultan et al. [18]. Our
mean rate of 91.3% total reads that map to the reference genome
met quality standards of the RNA-seq technique [19]. A breadth
of the RNA sequencing reads covering chromosome 1 indicates
quality RNA-seq coverage (Fig. 1). Hence, we are confident that
our mRNA-Seq data provide a good quality and objective profile
of transcriptome in human pulmonary microvascular endothelial
cells treated with thrombin. In addition, a qRT-PCR experiment
Table 3. Top ten up- and down- regulated novel isoforms in thrombin treated HMVEC Cells.
Gene Description Coordinates Length
FPKM
Control
FPKM
Thrombin
Fold
Change p-value Ensembl Gene ID
ITFG2 integrin alpha FG-GA
repeat containing 2
chr12:2921756–2939432 2257 0.00521437 2.2491 431.33 2.87E-05 ENSG00000111203
SEC16A SEC16 homolog A (S.
cerevisiae)
chr9:139334541–139378220 8173 0.0491136 7.40764 150.83 0 ENSG00000148396
PMS2P11 postmeiotic segregation
increased 2 pseudogene 11
chr7:76589124–76681310 668 0.00371097 0.359467 96.87 0 ENSG00000241350
- Genes nearby: ZFHX3
RNU7-71P
chr16:72816785–73092558 5767 0.00181948 0.0994668 54.67 0 ENSG00000140836
ENSG00000251868
SPTBN2 spectrin, beta, non-
erythrocytic 2
chr11:66449988–66496487 8426 0.0542375 2.86062 52.74 0 ENSG00000173898
MCAM melanoma cell adhesion
molecule
chr11:119170201–119187947 1795 0.514138 26.8537 52.23 0 ENSG00000076706
FBN2 fibrillin 2 chr5:127593698–127873129 4871 0.00400303 0.187473 46.83 0.0117604 ENSG00000138829
PHF21A PHD finger protein 21A chr11:45950885–46143027 7299 0.0236083 1.05125 44.53 0 ENSG00000135365
- Genes nearby: none chr19:56115009–56128567 3736 0.00705679 0.306568 43.44 0.0001756
- Genes nearby: none chr19:56115009–56128567 947 0.00746101 0.321088 43.04 0
ZNF518A zinc finger protein 518A chr10:97889630–97924859 9138 0.313598 0.000338024 2927.74 0.018282 ENSG00000177853
MYST4 MYST histone
acetyltransferase
(monocytic leukemia) 4
chr10:76585061–76792325 7557 0.124027 0.000147896 2838.61 0 ENSG00000156650
ZNF518A zinc finger protein 518A chr10:97889630–97924859 9351 0.319225 0.000432489 2738.11 0.0194973 ENSG00000177853
- Genes nearby: SENP7
ZNF90P1
chr3:101043117–101232085 452 1.25099 0.003021 2414.1 0 ENSG00000138468
ENSG00000241738
ZNF518A zinc finger protein 518A chr10:97889630–97924859 9452 0.216304 0.000826257 2261.79 0.002249 ENSG00000177853
- Genes nearby: none chr10:27855765–27870612 1031 0.27927 0.00107217 2260.47 0
RBMX RNA binding motif
protein, X-linked
chrX:135951349–135962911 4282 3.57287 0.0152633 2234.08 0 ENSG00000147274
E2F6 E2F transcription factor 6 chr2:11584508–11606270 1439 0.374663 0.00191853 2195.29 0.0034366 ENSG00000169016
PTBP2 polypyrimidine tract
binding protein 2
chr1:97187347–97280539 3131 0.505582 0.00259479 2194.84 0.0153448 ENSG00000117569
- Genes nearby: NTPCR
PCNXL2
chr1:233086321–233431177 1397 0.315314 0.00170047 2185.43 0 ENSG00000135778
ENSG00000135749
Novel Isoforms significantly differentially expressed as determined by CuffDiff, after Benjamini-Hochberg correction. The fold change is the ratio of thrombin FPKM to
control FPKM. The novel isoforms were ranked on their fold change and the 10 with the highest or lowest fold changes are listed here.
doi:10.1371/journal.pone.0031229.t003
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FANCD2) confirmed our results from RNA-seq. This adds more
weight to the credibility of our RNA-seq data in this study.
Although thrombin is known for its central role in the
coagulation cascade acting as both a coagulant factor and an
anticoagulant factor, thrombin can trigger important cellular
effects via a protease-activated receptor pathway or receptor
independent pathways [2]. The list of physiological and patho-
logical roles of thrombin is expanding. In the present study, we
performed a comprehensive transcriptome analysis in human
pulmonary microvascular endothelial cells (HMVEC-L) treated
with or without thrombin using the Illumina RNA-seq technique.
The aim of this study is to provide a comprehensive gene
expression profile of HMVEC-L treated with thrombin to gain a
complete picture of the transcriptional regulation of vascular
endothelial cells by thrombin since the dysregulation of vascular
endothelial cells by different agonists including thrombin has been
implicated in the development of a number of pathologic
disorders, such as inflammatory conditions, cancer, diabetes and
coronary heart diseases. Thrombin plays an important role in
vascular inflammation [11]. However, the full repertoire of players
and signal transduction pathways of this process are not
completely understood. We found that TNF receptor-associated
factor 1 and chemokine C-X3-C motif ligand 1 (C-X3-CL1), both
of which are involved in inflammatory response, were among the
top ten upregulated genes by thrombin (Figure 2). Inflammatory
response is among the top networks and canonical pathways of
both upregulated genes and isoforms by the thrombin treatment
Table 4. Networks affected by up-regulated genes/isoforms after thrombin treatment of HMVEC cells.
Up regulated genes
Networks Score Genes
Inflammatory Response, Cell-To-Cell Signaling and Interaction, Hematological System Development and Function 41 34
Inflammatory Response, Inflammatory Disease, Skeletal and Muscular Disorders 38 32
Cellular Growth and Proliferation, Tissue Morphology, Cellular Movement 24 24
Up regulated isoforms
Networks Score Genes
Hematological System Development and Function, Tissue Morphology, Cellular Growth and Proliferation 102 70
Cell Death, Cell Cycle, Cellular Growth and Proliferation 45 45
Cellular Growth and Proliferation, Cellular Movement, Cell Death 23 30
Inflammatory Disease, Connective Tissue Disorders, Skeletal and Muscular Disorders 20 28
Networks significantly down-regulated by thrombin treatment as determined by Ingenuity Pathway Analysis. The score is based on the p-value calculation. Networks
with a score of 15 or greater were defined as significant.
doi:10.1371/journal.pone.0031229.t004
Table 5. Top networks affected by down-regulated genes/isoforms after thrombin treatment of HMVEC cells.
Down regulated genes
Networks Score Genes
DNA Replication, Recombination, and Repair, Molecular Transport, Cellular Growth and Proliferation 27 33
Cell Cycle, Cancer, Cellular Growth and Proliferation 22 33
Cancer, Cellular Development, Organismal Injury and Abnormalities 16 33
Cellular Growth and Proliferation, Cancer, Cell Cycle 16 33
Cell Death, Cellular Movement, Cellular Growth and Proliferation 16 33
Inflammatory Response, Antimicrobial Response, Cell-To-Cell Signaling and Interaction 15 32
Down regulated isoforms
Networks Score Genes
Cancer, Cell Cycle, Cell Death 60 70
Connective Tissue Disorders, Genetic Disorder, Ophthalmic Disease 25 33
Cell Cycle, Cellular Growth and Proliferation, Cardiovascular System Development and Function 21 33
Cell Death, Cell Cycle, Post-Translational Modification 18 42
Cell Death, Cellular Growth and Proliferation, Cancer 16 40
Cell Death, Organismal Survival, Cellular Development 15 39
Networks significantly down-regulated by thrombin treatment as determined by Ingenuity Pathway Analysis. The score is based on the p-value calculation. Networks
with a score of 15 or greater were defined as significant.
doi:10.1371/journal.pone.0031229.t005
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vascular inflammation, but more importantly, they have provided
a complete list of differentially expressed genes after thrombin
treatment, as well as, full components in the top affected network
and canonical pathway of inflammatory response. By examining
differentially expressed genes in a traditional thrombin signaling
pathway (Figure 4), we found that thrombin receptor, Par 4 not
Par 1, was up-regulated at the 6 h thrombin treatment. This
makes sense since Par 1 is involved in an early response and Par 4
is involved in an later response of Thrombin. PARs contribute to
the proinflammatory phenotype observed in endothelial dysfunc-
tion [20]. Along the same line, expression of NFkB was
significantly up-regulated at the 6 h thrombin treatment. NF-kB
has been documented as the key regulator of inflammation [21].
The up-regulated Par4- and NF-kB-mediated effects may in part
contribute to the thrombin mediated inflammatory response as a
major affected transcriptional network or pathway in this study
although other genes in this traditionally annotated thrombin
pathway were either down-regulated or not affected (Table S4).
Several protocadherin alpha members such as PCDHA1,
PCDHA3 and PCDHA11 were among top upregulated genes
by thrombin (Figure 2 and Table S2). Figure 5 displays a full
spectrum of differential regulations of protocadherin alpha 1 to 13
by thrombin. Protocadherins are an important subfamily of the
Table 6. Top canonical pathways affected by up-regulated genes/isoforms after thrombin treatment of HMVEC cells.
Up regulated genes
Canonical Pathway p value Genes
Role of IL-17A in Psoriasis 0.000 23%
Differential Regulation of Cytokine Production in Macrophages and T Helper Cells by IL-17A and IL-17F 0.000 22%
TREM1 Signaling 0.000 19%
Role of Cytokines in Mediating Communication between Immune Cells 0.000 13%
Role of IL-17F in Allergic Inflammatory Airway Diseases 0.000 13%
Up regulated isoforms
Canonical Pathway p value Genes
Differential Regulation of Cytokine Production in Macrophages and T Helper Cells by IL-17A and IL-17F 0.000 28%
TREM1 Signaling 0.000 23%
TNFR2 Signaling 0.000 21%
Lymphotoxin b Receptor Signaling 0.000 15%
Acute Myeloid Leukemia Signaling 0.000 13%
CD40 Signaling 0.000 13%
Top canonical pathways significantly up-regulated by thrombin treatment as determined by Ingenuity Pathway Analysis. Pathways with a p-value less than 0.05 defined
as significant.
doi:10.1371/journal.pone.0031229.t006
Table 7. Top canonical pathways affected by down-regulated genes/isoforms after thrombin treatment of HMVEC cells.
Down regulated genes
Canonical Pathway p value Genes
DNA Double-Strand Break Repair by Homologous Recombination 0.000 64%
DNA Double-Strand Break Repair by Non-Homologous End Joining 0.000 57%
Role of BRCA1 in DNA Damage Response 0.000 36%
Aldosterone Signaling in Epithelial Cells 0.001 19%
Role of CHK Proteins in Cell Cycle Checkpoint Control 0.004 29%
Down regulated isoforms
Canonical Pathway p value Genes
DNA Double-Strand Break Repair by Homologous Recombination 0.000 71%
DNA Double-Strand Break Repair by Non-Homologous End Joining 0.000 64%
Role of BRCA1 in DNA Damage Response 0.000 45%
Role of CHK Proteins in Cell Cycle Checkpoint Control 0.000 42%
RAN Signaling 0.011 39%
Top canonical pathways significantly down-regulated by thrombin treatment as determined by Ingenuity Pathway Analysis. Pathways with a p-value less than 0.05
defined as significant.
doi:10.1371/journal.pone.0031229.t007
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Thrombin Signaling pathway was constructed by Ingenuity. Those with 1.3 fold up- or down-regulated genes in our data were uploaded and
displayed into this pathway. Red color indicates up-regulation of gene expression and green down-regulated genes while white indicate no change
of gene expression. The detailed fold changes and full name of each gene or isoform were presented in Table S4.
doi:10.1371/journal.pone.0031229.g004
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adhesion molecules. They are also involved in many biological
processes, including cell recognition and cell signaling [22].
Network analysis of the top differentially regulated genes indicate
that Cell-To-Cell Signaling and Interaction, Tissue Morphology,
and Cellular Movement are among the top affected networks by
the thrombin treatment (Table 4 and 5). These observations
provide a transcriptional level support and insight into known roles
of thrombin that can regulate cell-cell junctions between
endothelial cells as well as cytoskeleton contraction. Thrombin is
also recognized as a potent mitogen in cancer and tumor
metastasis [17]. We found that DNA Double-Strand Break Repair
and BRCA1 in DNA Damage Response were the top canonical
pathways of downregulated genes/isoforms after thrombin
treatment of HMVEC cells (Table 9). Dysfunction of the DNA
repair pathway is among the major causes of tumorogenesis [16].
Our observation may provide new molecular mechanisms
underlying thrombin in the tumor pathogenesis.
Previously, DNA microarray analysis has been performed to
profile gene expression pattern in human vascular endothelial cells
treated with thrombin. By comparing the RNA-seq data from this
study to those by Uzonyi et al. [23] in which gene expression
profile of 6 h thrombin treated HUVEC was assayed by
Affymetrix Human Genome U133A Array, we found that 38
genes were consistently up-regulated and 395 genes were
consistently down-regulated in both datasets (Table S7). Many of
the changes we observed in gene expression between control and
thrombin group were similar to those reported. For example, the
upregulation trend of several inflammatory response genes
(CX3CL1, 6.05 fold; VCAM1, 4.75 fold; ICAM1, 3.29 fold;
IL6, 2.27 fold; NFkB2, 2.02 fold) in thrombin treated HMVEC-L
cells revealed by RNA-seq in this study is the same as that detected
using DNA microarray array (CX3CL1, 1.39 fold; VCAM1, 4.16
fold; ICAM1, 3.14 fold; IL6, 1.34 fold; NFkB2, 1.41 fold) by
Uzonyi et al. [23]. Generally, RNA-seq is much more sensitive
than DNA microarray to detect the magnitude of difference in
differentially expressed genes after the thrombin treatment. Some
highly expressed genes or isoforms such as AS3MT (6.96 fold q)
and PCDHA11 (58.5 fold q) as well as lowly expressed genes and
isoforms in this study were not detected in DNA microarray [23].
Although the slightly different cell type and old DNA microarray
chips may be contributing factors to some of the disconcordance
between our RNA-seq transcriptome data set and the result of
DNA microarray, these differences most likely stem from inherent
limitations in microarray systems. We also compared the data
from this study to those by Viemann et al. [24] in which gene
expression profile of 5 h TNFa treated HMVEC was assayed by
Affymetrix Human Genome U133A Array. We found that 49
genes were consistently up-regulated and 264 genes were
consistently down-regulated in both datasets (Table S8). TNFa
Figure 6. qRT-PCR validation of three differentially expressed genes from thrombin-treated HMVEC RNA-Seq data. qRT-PCR was
carried out as described in the Method. Fold changes determined from the relative Ct values of TaqMan Gene Expression assay for CUGBP, Elav-
like family member 1 (CELF1), Fanconi anemia, complementation group D2 (FANCD2) and TNF receptor-associated factor 1 (TRAF1) were compared
to those detected by RNA-seq. Replicates (n=4) of each sample were run and the Ct values averaged. All Ct values were normalized to beta-actin. The
error bars represent the range of the fold change as determined by the Data Assist software.
doi:10.1371/journal.pone.0031229.g006
Figure 5. Protocadherin Alpha expression levels. A. RNASeq read density aligned to the reference for PCDHA. The RNASeq read density
plotted along PCDHA is shown. Average alignment was computed by igvtools. Each bar represents the frequency of reads along the gene for the
combined samples. B. Histogram of Protocadherin Alpha fold changes. A histogram showing the fold changes between thrombin-treated
HMVEC cells and control cells, as calculated by CuffDiff. The fold change is the ratio of FPKM of PCDHA isoforms in thrombin treated HMVEC to FPKM
of those in control cells.
doi:10.1371/journal.pone.0031229.g005
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[25]. Several upregulated genes known to be invovled in the
inflammatory response such as NFkB2, VCAM1, ICAM1, IL6,
IL8, TNFRSF9 were similarly detected in 5 h TNFa treated
HMVEC and 6 h thrombin treated HMVEC in our study though
the reported magnitude of increased expressions were different.
These cross comparisons between our RNA-seq data and those of
DNA microarray analysis of either 6 h thrombin treated HUVEC
or 5 h TNFa treated HMVEC have provided a significant
overlapping list of differentially expressed genes, supporting the
robust utility of our dataset. One notable advantage of RNA-seq is
that it can measure the less abundant transcripts that are
inaccurate or not detected by microarray. RNA-seq also enabled
the detection of unknown RNAs, alternative spliced transcripts
and alternative promoter usages which are not feasible by
microarray [6,26]. Indeed, our RNA-Seq study reveals nearly 1/
3 of the differentially expressed RNA transcripts are unannotated,
while about 26,000 novel isoforms are detected. Among those
novel isoforms, 418 were only detected in the control cells, while
424 were only detected in thrombin treated cells. The differentially
expressed novel isoforms in thrombin treated cells over the
controls with statistically significant fold changes ranged from
2927.74 to 431.33. There are 1,775 upregulated- and 12,202
downregulated- novel isoforms in thrombin treated cells by at least
a 2 fold change over the control cells (Table 2). This study has
provided rich reagents for further experimentation.
It should be pointed out that one limitation of our study is the
one time point, 6 h, of the thrombin treatment. The reason we
selected 6 h of thrombin treatment was based on at least the
following three references: 1). Simoncini et al. showed that
thrombin mediated upregulation of TNFSF10 (TRAIL), a TNF-a
superfamily inflammatory cytokine that displays multiple effects on
endothelial cells, started to peak at 6 h time point in both human
microvascular endothelial cells and HUVEC as quantified by real-
time PCR [27]. 2). Moser et al. showed that a 6 h thrombin
treatment significantly enhanced the adhesive interaction of
neutrophils to HUVEC as IL-1, TNF and LPS did compared to
those of the 5 min thrombin treatment [28]. A transendothelial
neutrophil passage is one of hallmark features in the inflammatory
process. 3) Liu et al. employed a 6 h thrombin treatment to
investigate thrombin mediated myocyte-specific enhancer factor-2
(MEF2)-dependent gene transcription of endothelial cells in
angiogenesis [29]. Our data from this study have provided a
valuable global picture on the thrombin mediated up-regulation
and down-regulation of multiple genes in the endothelium at the
6 h thrombin treatment as discussed above. Nevertheless, previous
studies have showed that of the genes that were induced by
thrombin, some peaked at 1 hour, some at 4 hours, and some at
18 hours [30]. Our study with 6 h thrombin treatment failed to
detect early and late thrombin response genes. It is certainly
warranted that a series of time course experiments of thrombin
treatment should be carried out to systematically survey the
transcriptional regulation of thrombin on endothelial cells to
provide more complete and dynamic datasets using the new and
powerful RNA-seq technology. A better understanding of the
temporal dynamics of these thrombin regulated transcriptional
networks may help to decipher the link between thrombin
signaling in the endothelium and multiple phenotypic changes.
In summary, our first complete transcriptome analysis of human
pulmonary microvascular endothelial cells treated with thrombin
using the RNA-seq has provided important insights into the
transcriptional regulation of gene expression in HMVEC-L cells
by thrombin. Further in-depth follow-up analysis of the transcrip-
tional regulation reported in this study may shed light on
molecular mechanisms underlying thrombin mediated endothelial
dysfunction in the pathogenesis of inflammatory conditions,
cancer, diabetes, coronary heart disease and provide new leads
of therapeutic targets to those diseases.
Materials and Methods
Cell culture and RNA isolation
Human Lung Microvascular Endothelial Cells (HMVEC,
Lonza catalog # CC-2815) were cultured as described previously
[31]. Briefly, cells were grown to 90–100% confluence on the 7
th
passage in T-75 flasks in EGM-2 medium with 5% FBS, growth
factors and antibiotics (Lonza, Bullet Kit catalog # CC-3202).
Media was changed to a starvation media (0% FBS) 30 minutes
prior to treatment. The cells were treated with 0.05 U/ml
thrombin (Sigma-Aldrich, catalog # T4393, Lot 087K7575) or
left untreated for 6 hours at 37uC. Total RNA was isolated from
the treated and control cells using the MirVana kit (Ambion,
catalog # AM1560) according to manufacturer’s instructions.
Library preparation and sequencing
Concentration of the RNA samples was determined using the
Quant-iT RiboGreen Kit (Invitrogen catalog # R11490)
according to manufacturer’s instructions. Each sample was assayed
3 times and the results averaged. The quality of the RNA was
checked using the RNA Std Sense Chip on the Bio-Rad Experion
system (catalog # 700-7103). The RNA was prepared for
sequencing using the TruSeq RNA Sample Prep Kit, Set A
(Illumina catalog # FC-122-1001) according to manufacturer’s
instructions. Each sample was prepared in duplicate and 2 mg total
RNA was used. The resulting cDNA libraries were quantified
using the Epoch system and checked for quality and size using the
Experion DNA 1K chip (catalog # 700-7107). A portion of each
library was diluted to 10 nM and stored at 220uC. 2 mL of the
10 nM libraries were diluted and denatured, according to
instructions from Illumina. The resulting cDNA was diluted to
5 pM and 1% PhiX control (Illumina catalog # FC-110-3001)
was spiked in each sample. A 6 pM dilution of PhiX Control was
also prepared. The samples were loaded on to the cBot (Illumina)
for clustering on a flow cell according to manufacturer’s
instructions.
The flow cell was then sequenced using a HiScanSQ (Illumina)
according to manufacturer’s instructions. A paired-end (26101)
run was performed using the SBS Kit (Illumina catalog # FC-401-
1001). Real-time analysis and basecalling was performed using the
HiSeq Control Software Version 1.3.8 (Illumina).
Primary processing of Illumina RNA-Seq reads
The number of clusters detected,percentage of those clusters
passing the software’s internal filter and the alignment to the PhiX
genome were all within acceptable limits. The resulting .bcl files
were converted first to .qseq files using Illumina’s Off-Line
Basecaller (OLB) and the .qseq files were subsequently converted
to FASTQ files. The sequence data have been submitted to the
NCBI Short Read Archive with accession number SRA046349.2.
Mapping of RNA-Seq reads and transcript assembly and
abundance estimation using Tuxedo Suite
The sequences were aligned to the UCSC Homo sapiens reference
genome hg19 using TopHat v1.3.0 [32], which is integrated with
Bowtie v0.12.7 [33]. TopHat removes a small number of reads
based on quality scoring accompanying each read and then maps
the reads to a provided reference genome. The pre-built UCSC H.
sapiens hg19 bowtie index was downloaded from the Illumina FTP
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sapiens_UCSC_hg19.tar.gz). TopHat’s default settings were used:
40 alignments per read were allowed, with up to 2 mismatches per
alignment. Each contiguously-mapping read is considered a
‘‘coverage island,’’ which are often spliced together with neighbor-
ing ‘‘islands.’’ These ‘‘islands’’ can be considered probable exons.
TopHat uses this initial mapping to build a database of potential
splice junctions and verifies them by comparing the previously
unmapped reads against the junction database.
The resulting aligned reads were analyzed further by Cufflinks
v1.0.3 [34] in several ways. Cufflinks assembled the aligned reads
into transcripts, either with or without a reference genome and
reported the expression of those transcripts in Fragments Per Kilobase
of exon per Million fragments mapped (FPKM). FPKM is an expression
of the relative abundance of transcripts. To determine differential
expression of known isoforms between the treatment and control
groups, Cuffdiff analyses were performed using the reference
genome comparing the thrombin treatment samples to the control
samples. The biologic replicates were pooled for those analyses. To
detect novel isoforms, Cufflinks was run without a reference
genome. This method allows the construction of the minimum
number of transcripts that described the data without a bias
towards already discovered transcripts. The sample transcript files
were then compared to the reference genome using Cuffcompare,
effectively filtering out those already-discovered transcripts. To test
the differential expression of these novel isoforms, Cuffdiff analyses
were performed using the combined transcript files as the
reference genome. Cuffdiff analyses were performed two ways:
comparing the thrombin transcripts to the control transcripts,
using the thrombin transcripts as the reference genome; and
comparing the thrombin transcripts to the control transcripts,
using the control transcripts as the reference genome.
Visualization of mapped reads
Aligned reads were visualized using a local copy of the
Integrative Genomics Viewer (www.broadinstitute.org/igv/).
The output files generated from TopHat were converted into files
viewable in IGV by BEDTools [35] and then further processed by
the ‘‘count’’ function in igvtools (included with the IGV software)
to create an average alignment track viewable as a bar chart. The
log2 of the frequency of the reads was plotted to better visualize the
extensive range of the read coverage. Individual gene views were
created by first merging the TopHat output files from the control
and thrombin-treatment samples into two files using SAMTools
[36]. These merged files were processed in the same way as above
with the ‘‘count’’ function in igvtools. The raw frequency of the
reads was visualized in this case.
Functional analysis of differentially expressed gene lists
using Ingenuity Pathway Analysis
The differentially expressed gene lists were submitted to
Ingenuity Pathway Analysis (IPA) v9.0-3211 (Ingenuity Systems,
Inc., Redwood City, CA). Genes with a 2-fold or greater change in
expression after thrombin treatment were uploaded to the
application. Each identifier was mapped to its corresponding
object in Ingenuity’s Knowledge Base. These molecules, called
Network Eligible molecules, were overlaid onto a global molecular
network developed from information contained in Ingenuity’s
Knowledge Base. Networks of Network Eligible Molecules were
then algorithmically generated based on their connectivity. The
following settings were used: Ingenuity Knowledge Base; Endog-
enous Chemicals not included; Direct and Indirect relationships;
molecules per pathway: 70; and networks per analysis: 25.
Canonical pathways analysis identified the pathways from the
Ingenuity Pathways Analysis library of canonical pathways that
were most significant to the data set. Genes with a 2-fold or greater
change in expression after thrombin treatment and that were
associated with a canonical pathway in Ingenuity’s Knowledge
Base were considered for the analysis. The significance of the
association between the data set and the canonical pathway was
measured in 2 ways: 1) the ratio of the number of molecules from
the data set that map to the pathway divided by the total number
of molecules that map to the canonical pathway, and 2) Fisher’s
exact test was used to calculate a p-value determining the
probability that the association between the genes in the dataset
and the canonical pathway is explained by chance alone.
Computer hardware specifications
TopHat, Bowtie and Cufflinks were installed and run on a
CentOS 5.5 Advanced Clustering Pinnacle 1BX5501 machine
with 20 nodes, totaling 240 cores and 960 GB RAM.
qRT-PCR Validation of RNA Seq Results
The following genes were selected for validation and TaqMan Gene
Expression Assays were ordered from Applied Biosystems (cat.
#4331182): CELF1 (Hs00198069_m1), FANDCD2 (Hs00276992_
m1), TRAF1 (Hs01090170_m1), and ACTB, as a control
(Hs99999903_m1). All genes were significantly differentially expressed
in our RNA Seq data as determined by Cufflinks. cDNA was made
from RNA previously isolated from control HMVEC and thrombin-
treated HMVEC. Gene expression assays were run according
to manufacturer’s instructions (www.appliedbiosystems.com) on a
Viia7 qPCR instrument. Replicates (n=4) of each sample were run.
The results were loaded into a local copy of DataAssist (www.
appliedbiosystems.com/dataassist) and normalized to ACTB Ct
values. The fold change and range of the fold change was calculated
for each gene.
Statistical Analysis
Besides those statistical tools embedded in Illumina HiScanSQ
instrument or other softwares, additional statistical analyses were
performed using Sigmaplot, a scientific data analysis and graphing
software (ver 12, Systat Software, Inc., San Jose, CA). Thrombin
treated groups were compared with the control groups by unpaired
Student’s t test. p,0.05 was considered statistically significant.
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